Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy

NCT03710603 is registered in ClinicalTrials.gov with Stichting European Myeloma Network as lead sponsor.

NCT NCT03710603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03710603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy
Lead sponsor
Stichting European Myeloma Network
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 14, 2018
Completion date
November 30, 2029
Enrollment
709 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma